While dupilumab has transformed the treatment of atopic dermatitis (AD), not all patients respond well, which may be due to underlying molecular heterogeneity. Therefore, researchers assessed if cytokine staining and/or histologic features are related to dupilumab response in patients with eczematous dermatitis.
Read more at the Journal of the American Academy of Dermatology.